A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy.

Autor: Cheng AYY; Department of Medicine, University of Toronto, ON, Canada; Trilium Health Partners & Unity Health, Toronto, Canada. Electronic address: Alice.Cheng@unityhealth.to., Mauricio D; Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau CIBERDEM, Barcelona, Spain., Ritzel R; Division of Endocrinology, Diabetes and Angiology, Klinikum Schwabing and Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Munich, Germany., Al-Sofiani ME; Division of Endocrinology, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University, Baltimore, MD, USA., Bailey T; AMCR Institute, Escondido, CA, USA., Aileen Mabunay M; Sanofi, Global Medical, Singapore, Singapore., Bonnemaire M; Sanofi, Paris, France., Melas-Melt L; Ividata Life Sciences, Levallois-Perret, France., Mimouni S; Pierre & Marie Curie Center, University of Algiers, Algiers, Algeria., Davies M; Diabetes Research Centre, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, Leicester, UK.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2024 Nov; Vol. 217, pp. 111871. Date of Electronic Publication: 2024 Sep 27.

Patient-reported outcomes and treatment adherence in type 2 diabetes using natural language processing: Wave 8 of the Observational International Diabetes Management Practices Study.

Autor: Chan JC; Department of Medicine and Therapeutics, Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China., Mbanya JC; Doctoral School of Life Sciences, Health and Environment, and Department of Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon., Chantelot JM; Sanofi, Paris, France., Shestakova M; Endocrinology Research Center, Moscow, Russia., Ramachandran A; India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India., Ilkova H; Istanbul University, Istanbul, Turkey., Deplante L; Quinten Health, Paris, France., Rollot M; Quinten Health, Paris, France., Melas-Melt L; IVIDATA Life Sciences, Levallois-Perret, France., Gagliardino JJ; CENEXA (UNLP-CONICET-Ce As CICPBA), School of Medicine UNLP, La Plata, Argentina., Aschner P; Javeriana University School of Medicine and San Ignacio University Hospital, Bogotá, Colombia.

Publikováno v: Journal of diabetes investigation [J Diabetes Investig] 2024 Sep; Vol. 15 (9), pp. 1306-1316. Date of Electronic Publication: 2024 Jun 05.

Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.

Autor: Giorgino F; Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari 70124, Italy. Electronic address: francesco.giorgino@uniba.it., Guja C; Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest 030167, Romania. Electronic address: cristian.guja@hotmail.com., Aydın H; Department of Endocrinology, Yeditepe University School of Medicine, Istanbul 34724, Turkey. Electronic address: hsnydn@yahoo.com., Lauand F; Sanofi, Paris 75017, France. Electronic address: felipe.lauand@sanofi.com., Melas-Melt L; Ividata Life Sciences, Levallois-Perret 92300, France. Electronic address: lydie.melas-melt-ext@sanofi.com., Rosenstock J; Velocity Clinical Research at Medical City, 75230 Dallas, TX, USA. Electronic address: jrosenstock@velocityclinical.com.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2024 Mar; Vol. 209, pp. 111604. Date of Electronic Publication: 2024 Mar 05.

Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.

Autor: Frechtel G; Departamento de Medicina, Orientación Nutrición, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina., Sauque-Reyna L; Instituto de Diabetes, Obesidad y Nutrición S.C., Cuernavaca, Mexico, Morelos, Mexico., Choza-Romero R; Centro Médico Ono, Aguascalientes, Mexico., Anguiano L; Medical Department, Sanofi, Mexico City, Mexico., Melas-Melt L; Ividata Life Sciences, Levallois-Perret, France., Sañudo-Maury ME; Medical Department, Sanofi, Mexico City, Mexico.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Sep; Vol. 25 (9), pp. 2526-2534. Date of Electronic Publication: 2023 May 30.

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.

Autor: Wray S; Hope Neurology, Knoxville, TN, USA., Jacques F; Clinique Neuro-Outaouais, Gatineau, Canada., Miller TA; Advanced Neurology of Colorado, Fort Collins, CO, USA., Nicholas JA; OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital, Columbus, OH, USA., Arroyo R; Hospital Universitario Quirónsalud Madrid, Madrid, Spain., Travis L; The MS Center of Arizona, Center for Neurology and Spine, Phoenix, AZ, USA., Khatri B; MD Center of Neurological Disorders, Milwaukee, WI, USA., Chirieac M; Sanofi, Cambridge, MA, USA., Gandhi R; Sanofi, Cambridge, MA, USA., Roesch N; Sanofi, Cambridge, MA, USA., Rodrigues A; Ividata Life Sciences, Levallois-Perret, France., Melas-Melt L; Ividata Life Sciences, Levallois-Perret, France., Rawlings AM; Sanofi, Cambridge, MA, USA., Hunter SF; Advanced Neuroscience Institute, Franklin, TN, USA.

Publikováno v: Multiple sclerosis journal - experimental, translational and clinical [Mult Scler J Exp Transl Clin] 2022 Nov 15; Vol. 8 (4), pp. 20552173221135888. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022).